The eye injection that treats wet macular degeneration on a monthly basis is ranibizumab, sold under the brand name Lucentis. Approved by the FDA in June 2006, it was the first anti-VEGF therapy developed specifically for wet age-related macular degeneration, and its recommended dosing schedule calls for a 0.5 mg intravitreal injection once every 28 days. In clinical trials, monthly Lucentis injections maintained vision in more than 90% of patients and meaningfully improved vision in roughly 40%. For the estimated 1.49 million Americans living with late-stage, vision-threatening AMD, that kind of result was groundbreaking — and it remains the benchmark against which newer treatments are measured.
But Lucentis is not the only option, and monthly dosing is not the only schedule. Several other anti-VEGF injections now compete for the same job, some requiring fewer visits to the retina specialist’s office. The tradeoffs involve cost, convenience, and in some cases, different safety profiles. For families already managing dementia care or cognitive decline in an aging parent, adding monthly eye appointments to the calendar is no small thing — and understanding which drugs allow longer intervals between injections can make a real difference in quality of life. This article walks through how these injections work, what they cost, how they compare to each other, and what emerging gene therapies could mean for the future of wet AMD treatment.
Table of Contents
- How Does the Monthly Eye Injection for Wet Macular Degeneration Actually Work?
- What Are the FDA-Approved Anti-VEGF Drugs and How Do Their Schedules Compare?
- The Staggering Cost Difference Between On-Label and Off-Label Injections
- Biosimilars and How They Could Change What Families Pay
- Why Missing Injections Is Dangerous, Especially for Patients With Cognitive Decline
- What Roughly 20 Million Americans With AMD Need to Know About Screening
- Gene Therapy and the Future of Treating Wet AMD With a Single Injection
- Conclusion
- Frequently Asked Questions
How Does the Monthly Eye Injection for Wet Macular Degeneration Actually Work?
All anti-VEGF injections for wet AMD target the same biological problem. In a healthy eye, the macula — the small central area of the retina responsible for sharp, detailed vision — sits on a stable foundation of blood vessels. In wet AMD, the body produces excess vascular endothelial growth factor, a protein that triggers the growth of abnormal, fragile blood vessels beneath the retina. These vessels leak blood and fluid, damaging the macula and causing the rapid central vision loss that makes wet AMD so devastating. Though wet AMD accounts for only about 10% of all AMD cases, it is responsible for 90% of AMD-related legal blindness, according to the BrightFocus Foundation.
Anti-VEGF drugs work by blocking that growth factor before it can do its damage. A retina specialist injects the medication directly into the vitreous — the clear gel that fills the interior of the eye — using a very fine needle. The procedure itself takes only a few minutes, though the prep and monitoring around it add time to the appointment. Numbing drops are applied beforehand, and most patients describe the sensation as pressure rather than sharp pain. Common side effects include temporary eye redness, mild eye pain, floaters, and occasionally increased eye pressure. For someone like a 78-year-old woman already dealing with early-stage Alzheimer’s, the injection itself may be less of a challenge than remembering the appointment schedule — which is one reason the dosing interval matters so much when choosing a treatment.
What Are the FDA-Approved Anti-VEGF Drugs and How Do Their Schedules Compare?
Six anti-VEGF drugs are currently used to treat wet AMD in the United States, and they differ significantly in how often they need to be injected. Lucentis (ranibizumab) set the standard with its monthly schedule. Eylea (aflibercept 2 mg) requires monthly injections for the first three loading doses, then typically moves to every eight weeks. Eylea HD (aflibercept 8 mg), a higher-dose formulation approved more recently, can extend intervals to 12 or even 16 weeks after the initial monthly loading period. Beovu (brolucizumab) follows a similar pattern — monthly for three months, then every 8 to 12 weeks.
And Vabysmo (faricimab-svoa), which targets both VEGF and a second protein called angiopoietin-2, has shown that roughly 80% of patients can extend to every three months or longer after four initial monthly doses, with more than 60% reaching every four months. However, a longer interval between injections does not automatically make a drug the best choice for every patient. Beovu, for instance, was associated with reports of intraocular inflammation and retinal vasculitis after its launch, prompting some retina specialists to reserve it for patients who have not responded well to other options. If a patient has trouble tolerating one drug or develops side effects, switching to another anti-VEGF agent is common practice. The important thing for caregivers to understand is that the first three months of treatment almost always require monthly visits regardless of which drug is chosen — there is no shortcut past the loading phase. Expecting a lighter schedule from day one will lead to frustration and, more importantly, could lead to undertreating the disease.
The Staggering Cost Difference Between On-Label and Off-Label Injections
The financial dimension of wet AMD treatment is difficult to overstate. A single injection of Lucentis runs approximately $1,800 to $2,000. At a monthly schedule, that adds up to roughly $22,960 per year. Eylea costs about $1,850 to $2,000 per injection, with first-year costs reaching an estimated $26,718 for monthly dosing during the loading phase, dropping to around $13,359 per year once a patient moves to bimonthly maintenance. Vabysmo, the newest on-label option, costs approximately $2,190 per injection. These are the prices before insurance — and while Medicare Part B covers most anti-VEGF injections, copays and supplemental coverage gaps still leave many patients with meaningful out-of-pocket costs.
Then there is Avastin (bevacizumab). Originally developed and FDA-approved as a cancer drug, Avastin is used off-label for wet AMD at a cost of roughly $55 to $70 per injection — meaning an entire year of monthly treatment runs approximately $720 to $840. The landmark CATT trial, one of the most important studies in retinal medicine, found Avastin equivalent in efficacy to Lucentis when given on similar dosing schedules. That finding has saved Medicare patients an estimated $17.3 billion over the years. The catch is that because Avastin is not FDA-approved for eye use, it must be repackaged by compounding pharmacies into smaller doses, which introduces a small but real risk of contamination. Most retina practices use reputable compounding sources and have administered Avastin safely for years, but patients and caregivers should feel comfortable asking their doctor about where the drug is sourced.
Biosimilars and How They Could Change What Families Pay
The patent landscape for anti-VEGF drugs has shifted substantially in recent years. Two ranibizumab biosimilars and six aflibercept biosimilars are now FDA-approved in the United States. Biosimilars are not generics in the traditional sense — they are biologic medications demonstrated to have no clinically meaningful differences from the reference product in terms of safety, purity, and potency. Their arrival is expected to exert downward pressure on prices, much as generic drugs do in other therapeutic areas, though the actual savings patients see will depend on insurance negotiations, pharmacy benefit structures, and how aggressively the biosimilar manufacturers price their products. For families managing both dementia care and wet AMD treatment, the financial calculus matters.
Cognitive decline often means a caregiver is accompanying the patient to every appointment, taking time away from work or other responsibilities. If a biosimilar can deliver the same visual outcomes as Lucentis or Eylea at 60% or 70% of the cost, that savings compounds over years of treatment. The tradeoff to watch for is whether retina specialists adopt biosimilars quickly or stick with the branded products they know. Ask directly — most doctors will be transparent about which products they stock and why. If cost is a barrier to consistent treatment, raising the biosimilar question is worth the conversation.
Why Missing Injections Is Dangerous, Especially for Patients With Cognitive Decline
The single biggest risk factor for poor outcomes in wet AMD treatment is not the drug chosen — it is inconsistent treatment. Anti-VEGF injections do not cure the disease. They manage it by suppressing the abnormal blood vessel growth that damages the macula. When injections are delayed or skipped, those vessels can regrow and leak again, sometimes causing irreversible damage that no subsequent injection can undo. A patient who maintains a strict injection schedule for two years and then falls off for six months may lose vision that was previously stable. This is where the overlap between wet AMD and dementia becomes especially treacherous.
A patient with mild cognitive impairment may forget appointments, resist leaving the house, or become anxious about a medical procedure they no longer fully understand. Caregivers may be stretched thin, juggling neurology visits, medication management, and daily living support. Monthly injections can feel like one obligation too many. But the consequences of letting treatment lapse are severe — central vision loss from wet AMD does not come back. If a patient is struggling with the monthly schedule, talk to the retina specialist about whether a drug with longer dosing intervals, like Vabysmo or Eylea HD, might be appropriate. Switching from a monthly regimen to one that allows visits every three or four months could be the difference between sustained treatment and abandonment of it.
What Roughly 20 Million Americans With AMD Need to Know About Screening
An estimated 20 million Americans have some form of age-related macular degeneration, according to Prevent Blindness data from 2019. The vast majority have the dry form, which progresses slowly and has no injection-based treatment. But dry AMD can convert to wet AMD without warning, and when it does, the window for preserving vision is narrow. A person with dry AMD should be monitoring their vision with an Amsler grid at home — a simple card with a grid pattern that reveals distortions in central vision — and seeing an eye specialist at whatever interval their doctor recommends.
For families already dealing with a dementia diagnosis, it is easy for eye health to slip down the priority list. But vision loss compounds cognitive decline in ways that are not always obvious. A person who cannot see clearly is more likely to become disoriented, fall, withdraw from social engagement, and lose the ability to perform tasks that were helping maintain their independence. Routine eye exams are not a luxury in this population. They are a frontline defense.
Gene Therapy and the Future of Treating Wet AMD With a Single Injection
The most exciting frontier in wet AMD treatment is gene therapy — the possibility of a single injection that could eliminate or dramatically reduce the need for ongoing anti-VEGF shots. Several candidates are in late-stage clinical trials. ABBV-RGX-314, developed by AbbVie, is in Phase III trials (ATMOSPHERE and ASCENT) with data expected in 2026. Ixo-vec, from Adverum Biotechnologies, launched its Phase III ARTEMIS trial in March 2025, after Phase II data showed that fewer than 50% of treated patients needed any additional injections in the year following a single dose. 4D Molecular Therapeutics began its Phase III 4FRONT-1 trial in July 2025, comparing a single gene therapy injection against aflibercept given every eight weeks. And Sanofi’s SAR402663 received FDA Fast Track designation in September 2025, signaling the agency’s recognition of unmet need.
Beyond gene therapy, researchers are also investigating entirely different biological targets. ANX007, a complement C1q inhibitor, is in Phase 3 trials with data expected in the second half of 2026. If successful, it would represent the first non-VEGF injection therapy for wet AMD — a meaningful backup for patients who do not respond adequately to current drugs. None of these treatments are available yet, and gene therapy trials carry their own risks and unknowns. But for patients and caregivers weary of the monthly or bimonthly injection grind, the pipeline offers genuine reason to be watchful. The coming two years may reshape how wet AMD is managed for decades.
Conclusion
Wet macular degeneration is a relentless condition, but the tools to manage it are better and more varied than at any point in medical history. Lucentis set the standard for monthly anti-VEGF injections in 2006, and the drugs that followed — Eylea, Eylea HD, Beovu, Vabysmo, and the off-label workhorse Avastin — have given patients and doctors meaningful choices in balancing efficacy, cost, and convenience. Biosimilars are beginning to ease the financial burden, and gene therapy trials may eventually reduce or eliminate the need for repeated injections altogether.
For families navigating both dementia and vision loss, the practical challenge is consistency. The best drug in the world does nothing if the patient stops showing up for treatment. Choose a retina specialist who communicates clearly, ask about extended-dosing options if monthly visits are unsustainable, and do not let eye care fall off the radar because cognitive care feels more urgent. Vision preservation is cognitive preservation — they are not separate battles.
Frequently Asked Questions
Does the eye injection for wet macular degeneration hurt?
Most patients report feeling pressure rather than pain. Numbing drops are applied before the injection, and the needle used is extremely fine. Temporary redness, mild discomfort, and floaters are the most common side effects afterward.
How long does each injection appointment take?
The injection itself takes only a few minutes. However, check-in, dilation, imaging, and post-injection monitoring typically make the full appointment 60 to 90 minutes. For caregivers managing a patient with cognitive impairment, planning for the full time window is essential.
Is Avastin as safe as Lucentis or Eylea for wet AMD?
The CATT trial found Avastin equivalent in efficacy to Lucentis. The primary safety concern with Avastin is that it must be repackaged by compounding pharmacies for eye use, since it is FDA-approved only for cancer treatment. Most retina practices use well-established compounding sources, but it is reasonable to ask your doctor about their supplier.
Can I switch between anti-VEGF drugs during treatment?
Yes. Switching is common and may be recommended if a patient is not responding well to one drug, develops side effects, or could benefit from a longer dosing interval offered by a different agent. Your retina specialist can guide this decision.
Will Medicare cover anti-VEGF injections for wet AMD?
Medicare Part B typically covers anti-VEGF injections administered in a doctor’s office, including the off-label use of Avastin. However, copays and coverage gaps vary. Patients should verify their specific plan details and ask about financial assistance programs if cost is a barrier.
What happens if I miss several months of injections?
Wet AMD can reactivate and cause new damage when treatment is interrupted. Some vision loss from untreated flare-ups may be permanent. If injections have been missed, schedule an appointment with your retina specialist as soon as possible — resuming treatment can still protect remaining vision.
